Brukinsa Plus Rituximab Gets FDA Priority Review as a Possible Chemotherapy-Free First Treatment for Mantle Cell Lymphoma
The FDA has granted priority review to Brukinsa plus rituximab for previously untreated mantle cell lymphoma after a trial showed a 43% reduction in progression or death versus chemotherapy.
Medical Daily ·